ASX:TLXBiotechs
New Kidney and Brain Imaging Data Might Change The Case For Investing In Telix (ASX:TLX)
In early May 2026, Telix Pharmaceuticals reported new independent Phase 3 ZIRCON analyses in European Urology showing TLX250-Px PET/CT may predict malignancy across a broad range of renal cancer subtypes, alongside progress of its glioma imaging candidate TLX101-Px with a validated European marketing authorization application now under active review.
These updates highlight how Telix’s radiopharmaceutical imaging portfolio could extend beyond clear cell kidney cancer into non-clear cell...